Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Aberrant c-Met tyrosine kinase signaling drives tumor growth, metastasis, and resistance to cancer therapies.
• Targeting c-Met is a validated strategy for cancer treatment.

Purpose of the Study:

• To design, synthesize, and evaluate novel ATP-competitive inhibitors of c-Met tyrosine kinase.
• To identify potent and selective c-Met inhibitors with favorable drug-like properties.

Main Methods:

• Structure-activity relationship (SAR) studies were conducted on a series of 6-aryl-2-(3-(heteroarylamino)benzyl)pyridazinone compounds.
• Biological activities were assessed, including selectivity, potency against c-Met, pharmacokinetic properties in mice, and in vivo antitumor efficacy.

Main Results:

• A novel series of pyridazinone-based c-Met inhibitors were synthesized and characterized.
• Pyridazinone 19 emerged as a highly selective and potent inhibitor of c-Met tyrosine kinase.
• Compound 19 demonstrated favorable pharmacokinetic profiles in mice and significant antitumor activity in a c-Met-dependent EBC-1 xenograft model.

Conclusions:

• Novel pyridazinone derivatives effectively inhibit c-Met tyrosine kinase.
• Pyridazinone 19 represents a promising preclinical candidate for treating c-Met-driven cancers.
• The developed inhibitors offer a potential strategy to overcome therapeutic resistance mediated by c-Met.